5,042 Shares in Vericel Co. (NASDAQ:VCEL) Bought by Park Avenue Securities LLC

Park Avenue Securities LLC bought a new position in shares of Vericel Co. (NASDAQ:VCEL) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,042 shares of the biotechnology company’s stock, valued at approximately $262,000.

Several other institutional investors have also recently made changes to their positions in VCEL. DekaBank Deutsche Girozentrale purchased a new position in shares of Vericel during the fourth quarter worth $33,000. GAMMA Investing LLC acquired a new stake in Vericel during the fourth quarter valued at $65,000. Sentry Investment Management LLC acquired a new stake in Vericel during the fourth quarter valued at $136,000. PNC Financial Services Group Inc. grew its position in Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 344 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Vericel during the fourth quarter valued at $197,000.

Vericel Trading Down 1.9 %

VCEL opened at $45.03 on Tuesday. The firm has a market capitalization of $2.19 billion, a PE ratio of -4,498.50 and a beta of 1.70. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The firm’s 50-day moving average price is $46.58 and its 200 day moving average price is $44.62.

Vericel (NASDAQ:VCEL) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The company had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. During the same period in the previous year, the firm earned ($0.16) earnings per share. Vericel’s quarterly revenue was up 25.0% compared to the same quarter last year. As a group, analysts predict that Vericel Co. will post 0.11 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sean C. Flynn sold 6,772 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the sale, the insider now directly owns 487 shares of the company’s stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Sean C. Flynn sold 1,474 shares of Vericel stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $45.84, for a total value of $67,568.16. Following the completion of the transaction, the insider now owns 487 shares in the company, valued at $22,324.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean C. Flynn sold 6,772 shares of Vericel stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the transaction, the insider now owns 487 shares of the company’s stock, valued at approximately $21,924.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,246 shares of company stock valued at $1,924,869. Company insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on VCEL. HC Wainwright raised their price target on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, June 21st. Truist Financial restated a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. Finally, TD Cowen started coverage on shares of Vericel in a research report on Thursday, June 20th. They issued a “buy” rating and a $55.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $48.17.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.